Wire · market
Roundup: AbbVie & Lambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
AbbVie has entered a multi-year collaboration with Iambic to use its AI platform to accelerate small molecule drug discovery across several therapeutic areas, while Telix Pharmaceuticals is acquiring ITM to consolidate radiopharmaceutical production and strengthen its theranostic portfolio with FDA-stage assets.
This Wire brief sits within Fusion42's coverage of Drug Discovery, AI Frontier Models and Biotech, and 3 sources have reported it between 21 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
You can expect AI to reduce drug discovery time while raising molecule quality, enabling you to compete on innovation speed. Telix merging with ITM opens a new path to scale radiopharmaceutical manufacturing and access late-stage assets that could reshape your pipeline.
◆ Coverage
3 sources · first reported 21 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics